OncLive News Network: On Location at ASH 2021 - Episode 3
Updates in AML and MPNs From ASH 2021: From Drs Srdan Verstovsek and Naval Daver
OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.
Today-
We are reporting from the 2021 ASH Annual Meeting!
We have been highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.
Welcome to OncLive News Network! I’m Gina Mauro.
Primary results from the phase 3 ZUMA-7 trial showed that axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.
In a quality of life analysis of the ZUMA-7 trial, axicabtagene ciloleucel resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.
The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease in a phase 2 trial. Results indicated that 77% of those who went on to receive the triplet combination achieved undetectable minimal residual disease.
Asciminib demonstrated a consistent improvement in major molecular response rate and depth of response vs bosutinib in patients with chronic-phase chronic myeloid leukemia without any new or worsening adverse effects, according to updated findings from the phase 3 ASCEMBL trial.
Results from a meta-analysis of the phase 1/2 CARTITUDE-1 trial showed that ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.
Please be sure to check out more of our coverage from the 2021 ASH Annual Meeting at OncLive.com.
That’s all for today. Thank you for watching OncLive News Network: On Location. Signing off from the 2021 ASH Annual Meeting, I’m Gina Mauro.